Menu Search
Equities

Harvard Bioscience Inc

HBI:DUS

Harvard Bioscience Inc

Actions
  • Price (EUR)2.46
  • Today's Change0.02 / 0.82%
  • Shares traded--
  • 1 Year change-36.60%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 11:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Harvard Bioscience Inc has grown net income from a loss of -9.52m to a smaller loss of -3.42m despite relatively flat revenues.
Gross margin58.39%
Net profit margin-10.56%
Operating margin-4.94%
Return on assets-7.86%
Return on equity-14.97%
Return on investment-9.44%
More ▼

Cash flow in USDView more

In 2023, Harvard Bioscience Inc did not generate a significant amount of cash. However, the company earned 14.03m from its operations for a Cash Flow Margin of 12.50%. In addition the company used 1.80m on investing activities and also paid 12.13m in financing cash flows.
Cash flow per share-0.0822
Price/Cash flow per share--
Book value per share1.54
Tangible book value per share-0.0647
More ▼

Balance sheet in USDView more

Harvard Bioscience Inc has a Debt to Total Capital ratio of 34.67%, a lower figure than the previous year's 50.68%.
Current ratio2.05
Quick ratio0.9416
Total debt/total equity0.5306
Total debt/total capital0.3467
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.